Lilly’s former M&A chief scours the landscape for potential deals as Immunocore’s new CFO

Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.

By Michael Gibney • Feb. 20, 2025

Challenges mount for vaccine makers

End-of-year earnings reports reveal drugmakers are grappling with declining vaccination rates and an unpredictable Trump administration.

By Amy Baxter • Feb. 19, 2025

Explore the Trendline➔

Rare diseases

As drug developers find promise in the rare diseases, deals and treatments are on the rise

By PharmaVoice staff

Merck, Lilly launch manufacturing R&D consortium to help ‘bolster’ U.S. production

The Young Institute Pharmaceutical Manufacturing Consortium will research and develop new production technologies.

By Alexandra Pecci • Feb. 19, 2025

Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split

The two companies will let their long-running contract expire this year, and drugmakers will need to decide which is the best platform for them in a changing marketplace.

By Michael Gibney • Feb. 13, 2025

The kids are alright: How pharma can make inroads with Gen Z

As drug development priorities shift, pharma companies need to understand younger patients to improve their reputation.

By Amy Baxter • Feb. 12, 2025

In the crowded cardio space, it’s David vs. Goliath for small biotechs

What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.

By Alexandra Pecci • Feb. 11, 2025

Medicare’s next list of drugs for price negotiation could get ‘very interesting’ — and have a bigger impact on pharma

The Biden-era law is now in the hands of a new administration, and drugmakers are scanning the horizon for hints of a massive overhaul or incremental change.

By Michael Gibney • Feb. 11, 2025

Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments

Fractyl Health is entering pivotal studies for a procedure that aims to be an ‘off ramp’ to GLP-1s and exploring how a one-time, ‘smart GLP-1’ gene therapy can Treat type 2 diabetes.

By Amy Baxter • Feb. 10, 2025

Are orexins the next golden child of neuroscience?

An emerging class of orexin-based drugs are on the cusp of disrupting care for sleep disorders — and potentially much more.

By Meagan Parrish • Feb. 10, 2025

Bristol Myers gives first peek at closely watched launch of schizophrenia drug

Cobenfy, the main asset acquired through Bristol Myers’ $14 billion purchase of Karuna, had $10 million in sales in the fourth quarter and around 1,000 prescriptions weekly by late January.

By Jacob Bell • Feb. 7, 2025

Tariffs raise concern among generic drugmakers, and advocacy groups are seeking exemptions

While the 10% tariff on Chinese goods won’t have too much impact on branded drugs, generics are struggling to pivot.

By Kelly Bilodeau • Feb. 7, 2025

With uncertainty roiling Big Pharma, execs are placing lower-risk bets

The market has been no less demanding for pharma giants as 2025 begins, but last year’s strategies are paying off.

By Michael Gibney • Feb. 6, 2025

RFK Jr. will face these critical tests if confirmed as head of the HHS

After a Senate committee advanced President Trump’s nominee to lead HHS, Robert F. Kennedy Jr. is poised to secure the top job at the nation’s healthcare agency.

By Amy Baxter • Feb. 5, 2025

As financial headwinds pick up, pharmas are aiming to squeeze more ROI from their R&D

With assets under a knife and pipelines under a microscope, R&D programs are being overhauled to be more efficient and cost effective.

By Alexandra Pecci • Feb. 5, 2025

Looming USAID shutdown threatens global health presence and a legacy of medical foreign aid

As President Trump and his cohorts plan to shut down the U.S. Agency for International Development, here’s what that could mean for global health and the drugmaking industry.

By Michael Gibney • Feb. 4, 2025

What should pharma make of the FDA going dark on DEI?

After a series of potent executive orders last week, the FDA removed draft guidance on diversity in clinical trials.

By Meagan Parrish • Feb. 4, 2025

Drugmakers prep for bird flu outbreak, despite continued low risk

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are coming through the pipes if it does.

By Kelly Bilodeau • Feb. 3, 2025

A new, non-opioid pain drug is here. Getting it to patients could be agony.

After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful biotechs contend with a healthcare system that’s long favored opioids?

By Jacob Bell • Feb. 3, 2025

Pharma’s forecast for 2025: Sowing seeds of a rebound

Despite regulatory uncertainty, pharma is bouncing back from a market slump and is being fueled by innovation. 

By Meagan Parrish • Jan. 31, 2025

Is federal funding frozen? Has it already thawed? Flip-flop leaves biopharma on edge

NIH grants that help fund drug development were caught in the mix of confusing executive orders this week.

By Amy Baxter • Jan. 31, 2025

RFK Jr. faces reconciliation of past vaccine statements at Senate HHS hearing

“Are you supportive of these onesies?” Sen. Bernie Sanders asked Kennedy, pointing to infant clothing stamped with anti-vaccine slogans — and more from yesterday’s confirmation hearing.

By Michael Gibney • Jan. 30, 2025

A long-awaited alternative to opioids is on the FDA doorstep. Can Vertex seal the deal?

Vertex Pharmaceuticals’ non-opioid pain medication is up for FDA approval this week. Other drugmakers have found safer alternatives to expand the pain management landscape.

By Amy Baxter • Updated Feb. 4, 2025

Executive hiring changes reflect a broader biotech comeback

Executive hiring shifts are often indicators of wider trends in the market. Here’s how the hiring landscape for pharma leaders is changing.

By Alexandra Pecci • Jan. 29, 2025

Bringing drugs to market has ‘never been more challenging,’ and pharma is learning to adapt

As changes to the U.S. regulatory foundation take hold, pharmas need to change their strategies to keep innovation — and the bottom line — above the surface.

By Michael Gibney • Jan. 28, 2025

An ALS treatment wave is approaching, and this biotech CEO is ready to surf

Coya Therapeutics is entering into a phase 2b study for its ALS, and the biotech’s CEO believes it’s on the cusp of a game changer.

By Amy Baxter • Jan. 27, 2025